{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:06:15Z","timestamp":1792019175775,"version":"4.4.0"},"reference-count":118,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,18]],"date-time":"2023-10-18T00:00:00Z","timestamp":1697587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.phrs.2023.106966","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:42:45Z","timestamp":1697773365000},"page":"106966","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics"],"prefix":"10.1016","volume":"197","author":[{"given":"Kyle J.","family":"Rehrauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher W.","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2023.106966_bib1","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0022-3565(25)20227-0","article-title":"Selective blockage of delta opioid receptors prevents the development of morphine Q17 tolerance and dependence in mice","volume":"258","author":"Abdelhamid","year":"1991","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib2","unstructured":"Advantx. SIMU-101. PK PD of ADV502 in healthy volunteers and patients with chronic osteoarthritis pain. https:\/\/advantx.org\/clinical\/adv502-clinical-study-phase-1\/. Accessed 12 July, 2023."},{"key":"10.1016\/j.phrs.2023.106966_bib3","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2023.106966_bib4","doi-asserted-by":"crossref","first-page":"E118","DOI":"10.1208\/aapsj080114","article-title":"Opioid ligands with mixed mu\/delta opioid receptor interactions: an emerging approach to novel analgesics","volume":"8","author":"Ananthan","year":"2006","journal-title":"AAPS J."},{"key":"10.1016\/j.phrs.2023.106966_bib5","doi-asserted-by":"crossref","first-page":"8350","DOI":"10.1021\/jm300686p","article-title":"14-Alkoxy- and 14-acyloxypyridomorphinans: \u03bc agonist\/\u03b4 antagonist opioid analgesics with diminished tolerance and dependence side effects","volume":"55","author":"Ananthan","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib6","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1021\/jm990039i","article-title":"Synthesis, opioid receptor binding, and biological activities of naltrexone-derived pyrido- and pyrimidomorphinans","volume":"42","author":"Ananthan","year":"1999","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib7","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00204-018-2244-6","article-title":"Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects","volume":"92","author":"Baldo","year":"2018","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.phrs.2023.106966_bib8","first-page":"6","article-title":"Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies","volume":"6","author":"Befort","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib9","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1016\/j.bmcl.2012.05.042","article-title":"Identification of a dual \u03b4 OR antagonist\/\u03bc OR agonist as a potential therapeutic for diarrhea-predominant Irritable Bowel Syndrome (IBS-d)","volume":"22","author":"Breslin","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106966_bib10","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1021\/jm030548r","article-title":"Rationale, design, and synthesis of novel phenyl imidazoles as opioid receptor agonists for gastrointestinal disorders","volume":"47","author":"Breslin","year":"2004","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib11","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/ALN.0000000000002840","article-title":"Combination of a \u03b4-opioid receptor agonist and loperamide produces peripherally-mediated analgesic synergy in mice","volume":"131","author":"Bruce","year":"2019","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2023.106966_bib12","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1080\/17460441.2023.2216015","article-title":"Advances with the discovery and development of novel sigma 1 receptor antagonists for the management of pain","volume":"18","author":"Burns","year":"2023","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2023.106966_bib13","doi-asserted-by":"crossref","first-page":"6531","DOI":"10.1021\/jm2003238","article-title":"Structural determinants of opioid and NOP receptor activity in derivatives of buprenorphine","volume":"54","author":"Cami-Kobeci","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib14","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1021\/jm301783x","article-title":"Development of \u03ba opioid receptor antagonists","volume":"56","author":"Carroll","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib15","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1021\/jm00093a014","article-title":"Enantiomeric N-substituted N-normetazocines: a comparative study of affinities at \u03c3, PCP, and \u03bc opioid receptors","volume":"35","author":"Carroll","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib16","unstructured":"Centers for Disease Control and Prevention. 2018 Annual surveillance report of drug-related risks and outcomes \u2013 United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. Published August 31, 2018. Accessed July 9, 2023. https:\/\/www.cdc.gov\/drugoverdose\/pdf\/pubs\/2018-cdc-drug-surveillance-report.pdf."},{"key":"10.1016\/j.phrs.2023.106966_bib17","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1080\/17460441.2020.1767063","article-title":"An up-to-date overview of computational polypharmacology in modern drug discovery","volume":"15","author":"Chaudhari","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.phrs.2023.106966_bib18","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1021\/acsmedchemlett.1c00233","article-title":"\u201cI\u2019ll be back\u201d: The resurrection of dezocine","volume":"12","author":"Childers","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106966_bib19","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1097\/j.pain.0000000000000986","article-title":"Cebranopadol, a novel first-in-class analgesic drug candidate: first experience in patients with chronic low back pain in a randomized clinical trial","volume":"158","author":"Christoph","year":"2017","journal-title":"Pain"},{"issue":"Suppl 1","key":"10.1016\/j.phrs.2023.106966_bib20","first-page":"S153","article-title":"75 Years of opioid research: the exciting but vain quest for the Holy Grail","volume":"147","author":"Corbett","year":"2006","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bph.12612","article-title":"Challenges for opioid receptor nomenclature: IUPHAR Review 9","volume":"172","author":"Cox","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2019.03.006","article-title":"Bifunctional opioid receptor ligands as novel analgesics","volume":"151","author":"Cunningham","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2023.106966_bib23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/ALN.0000000000001529","article-title":"Respiratory effects of the nociceptin\/orphanin FQ peptide and opioid receptor agonist, cebranopadol, in healthy human volunteers","volume":"126","author":"Dahan","year":"2017","journal-title":"Anesthesiology"},{"key":"10.1016\/j.phrs.2023.106966_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-11189-6","article-title":"Attenuated G protein signaling and minimal receptor phosphorylation as a biochemical signature of low side-effect opioid analgesics","volume":"12","author":"Dasgupta","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2023.106966_bib25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.molmed.2020.07.002","article-title":"Meet your stress management professionals: The endocannabinoids","volume":"26","author":"deRoon-Cassini","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.phrs.2023.106966_bib26","doi-asserted-by":"crossref","first-page":"370","DOI":"10.3389\/fphar.2016.00370","article-title":"A personal retrospective: Elevating anandamide (AEA) by targeting fatty acid amide hydrolase (FAAH) and the fatty acid binding proteins (FABPs)","volume":"7","author":"Deutsch","year":"2016","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib27","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1021\/acschemneuro.8b00150","article-title":"DARK classics in chemical neuroscience: morphine","volume":"9","author":"Devereaux","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2023.106966_bib28","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1111\/bph.14199","article-title":"In vitro and in vivo characterization of the bifunctional mu and delta opioid receptor ligand UFP-505","volume":"175","author":"Dietis","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib29","doi-asserted-by":"crossref","first-page":"E5511","DOI":"10.1073\/pnas.1605295113","article-title":"A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates","volume":"113","author":"Ding","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.106966_bib30","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar3483","article-title":"A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates","volume":"10","author":"Ding","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.phrs.2023.106966_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-62530-w","article-title":"N-Phenethyl substitution in 14-methoxy-N-methylmorphinan-6-ones turns selective \u03bc opioid receptor ligands into dual \u03bc\/\u03b4 opioid receptor agonists","volume":"10","author":"Dumitrascuta","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.phrs.2023.106966_bib32","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ejmech.2019.05.037","article-title":"Preparation of bivalent agonists for targeting the mu opioid and cannabinoid receptors","volume":"178","author":"Dvor\u00e1csk\u00f3","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib33","first-page":"661","article-title":"Buprenorphine clinical pharmacokinetics in the treatment of opioid dependence","volume":"44","author":"Elkander","year":"2005","journal-title":"Clin. Pharmacokinet."},{"issue":"5 pt 1","key":"10.1016\/j.phrs.2023.106966_bib34","first-page":"G979","article-title":"5-HT4 receptor agonists and delta-opioid receptor antagonists act synergistically to stimulate colonic propulsion","volume":"275","author":"Foxx-Orenstein","year":"1998","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.phrs.2023.106966_bib35","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1021\/acs.jmedchem.9b01256","article-title":"4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane derivatives as dual \u03bc-opioid receptor agonists and \u03c31 receptor antagonists for the treatment of pain","volume":"63","author":"Garc\u00eda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib36","doi-asserted-by":"crossref","first-page":"15508","DOI":"10.1021\/acs.jmedchem.0c01127","article-title":"Discovery of EST73502, a dual \u03bc-opioid receptor agonist and a \u03c31 receptor antagonist clinical candidate for the treatment of pain","volume":"63","author":"Garc\u00eda","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib37","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/bph.12706","article-title":"Recent advances on the delta opioid receptor: from trafficking to function","volume":"172","author":"Gendron","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib38","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/JCP.0000000000000995","article-title":"Assessment of the abuse potential of cebranopadol in nondependent recreational opioid users: A Phase 1 randomized controlled study","volume":"39","author":"Gohler","year":"2019","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib39","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jpain.2013.06.008","article-title":"An overview of animal models of pain: disease models and outcome measures","volume":"14","author":"Gregory","year":"2013","journal-title":"J. Pain."},{"key":"10.1016\/j.phrs.2023.106966_bib40","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1021\/acschemneuro.9b00535","article-title":"DARK classics in chemical neuroscience: kratom","volume":"11","author":"Han","year":"2020","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2023.106966_bib41","doi-asserted-by":"crossref","first-page":"8072","DOI":"10.1073\/pnas.93.15.8072","article-title":"Purification, molecular cloning, and expression of the mammalian sigma1-binding site","volume":"93","author":"Hanner","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.phrs.2023.106966_bib42","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.bmcl.2016.11.057","article-title":"Benzylideneoxymorphone: a new lead for development of bifunctional mu\/delta opioid receptor ligands","volume":"27","author":"Healy","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106966_bib43","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1021\/acs.jmedchem.9b00219","article-title":"Structural simplification of a tetrahydroquinoline-core peptidomimetic \u03bc-opioid receptor (MOR) agonist\/\u03b4-opioid receptor (DOR) antagonist produces improved metabolic stability","volume":"62","author":"Henry","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1021\/acschemneuro.0c00693","article-title":"SAR matrices enable discovery of mixed efficacy \u03bc-opioid receptor agonist peptidomimetics with simplified structures through an aromatic-amine pharmacophore","volume":"12","author":"Henry","year":"2021","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.phrs.2023.106966_bib45","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/acs.jmedchem.9b01818","article-title":"Aromatic-amine pendants produce highly potent and efficacious mixed efficacy \u03bc-opioid receptor (MOR)\/\u03b4-opioid receptor (DOR) peptidomimetics with enhanced metabolic stability","volume":"63","author":"Henry","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib46","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/bs.mie.2017.06.017","article-title":"Endocannabinoid transport proteins: Discovery of tools to study sterol carrier protein-2","volume":"593","author":"Hillard","year":"2017","journal-title":"Methods Enzym."},{"key":"10.1016\/j.phrs.2023.106966_bib47","first-page":"440","article-title":"Clinical studies of morphine-nalorphine combinations","volume":"15","author":"Houde","year":"1956","journal-title":"Fed. Proc."},{"key":"10.1016\/j.phrs.2023.106966_bib48","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/bph.13534","article-title":"Opioid and cannabinoid synergy in a mouse neuropathic pain model","volume":"173","author":"Kazantzis","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib49","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased agonism: Lessons from studies of opioid receptor agonists","volume":"63","author":"Kelly","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.phrs.2023.106966_bib50","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1124\/jpet.106.111997","article-title":"SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin\/orphanin FQ\/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice","volume":"320","author":"Khroyan","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib51","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1016\/j.bja.2018.10.065","article-title":"BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates","volume":"122","author":"Kiguchi","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.phrs.2023.106966_bib52","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s00213-010-1819-6","article-title":"Kappa opioids and the modulation of pain","volume":"210","author":"Kivell","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2023.106966_bib53","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40262-017-0545-1","article-title":"Clinical pharmacokinetic characteristics of cebranopadol, a novel first-in-class analgesic","volume":"57","author":"Kleideiter","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.phrs.2023.106966_bib54","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.jpainsymman.2019.05.012","article-title":"Cebranopadol, a novel first-in-class analgesic drug candidate: First experience with cancer-related pain for up to 26 weeks","volume":"58","author":"Koch","year":"2019","journal-title":"J. Pain. Symptom Manag."},{"key":"10.1016\/j.phrs.2023.106966_bib55","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1021\/acs.jmedchem.9b00449","article-title":"Synthesis and structure-activity relationships of spirocyclic benzopyrans with exocyclic amino moiety","volume":"62","author":"Kronenberg","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib56","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/j.pain.0000000000000790","article-title":"Bifunctional peptide-based opioid agonist\/nociceptin antagonist ligand for dual treatment of nociceptive and neuropathic pain","volume":"158","author":"Lagard","year":"2017","journal-title":"Pain"},{"key":"10.1016\/j.phrs.2023.106966_bib57","doi-asserted-by":"crossref","first-page":"825","DOI":"10.3390\/molecules28020825","article-title":"Explaining accurate predictions of multitarget compounds with machine learning models derived for individual targets","volume":"28","author":"Lamens","year":"2023","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.106966_bib58","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0026-895X(25)13068-X","article-title":"Structural determinants of \u03c3 receptor affinity","volume":"32","author":"Largent","year":"1987","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib59","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S0022-3565(25)11395-5","article-title":"The analgesic effectiveness of nalorphine and nalorphine-morphine combinations in man","volume":"112","author":"Lasagna","year":"1954","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib60","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/jm4005219","article-title":"Bivalent ligands that target \u03bc opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance","volume":"56","author":"Le Naour","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jpain.2019.05.017","article-title":"A novel mu-delta opioid agonist demonstrates enhanced efficacy with reduced tolerance and dependence in mouse neuropathic pain models","volume":"21","author":"Lei","year":"2020","journal-title":"J. Pain."},{"key":"10.1016\/j.phrs.2023.106966_bib62","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1124\/jpet.114.213694","article-title":"Cebranopadol: a novel potent analgesic nociceptin\/orphanin FQ peptide and opioid receptor agonist","volume":"349","author":"Linz","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib63","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3390\/molecules24040740","article-title":"Fentanyl family at the mu-opioid receptor: uniform assessment of binding and computational analysis","volume":"24","author":"Lipi\u0144ki","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.106966_bib64","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.3390\/ijms23052766","article-title":"Fentanyl structure as a scaffold for opioid\/non-opioid multitarget analgesics","volume":"23","author":"Lipi\u0144ski","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2023.106966_bib65","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1039\/C9MD00222G","article-title":"Affinity of fentanyl and its derivatives for the \u03c31-receptor","volume":"10","author":"Lipi\u0144ski","year":"2019","journal-title":"Medchemcomm"},{"key":"10.1016\/j.phrs.2023.106966_bib66","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1007\/s00213-020-05638-1","article-title":"Behavioral effects of benzylideneoxymorphone (BOM), a low efficacy \u03bc opioid receptor agonist and a \u03b4 opioid receptor antagonist","volume":"237","author":"Mada","year":"2020","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2023.106966_bib67","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1021\/jm020889p","article-title":"Novel spiropiperidines as highly potent and subtype selective \u03c3-receptor ligands. Part 2. SAR of spiro[[2]benzopyran-1,4\u2032-piperidines] and spiro[[2]benzofuran-1,4\u2032-piperidines] with carbon substituents in position 3","volume":"45","author":"Maier","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib68","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1021\/jm010992z","article-title":"Novel spiropiperidines as highly potent and subtype selective \u03c3-receptor ligands. Part 1","volume":"45","author":"Maier","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib69","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0031-6997(25)07161-3","article-title":"Opioid antagonists","volume":"19","author":"Martin","year":"1967","journal-title":"Pharmacol Rev."},{"key":"10.1016\/j.phrs.2023.106966_bib70","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1124\/jpet.113.208108","article-title":"Orally active opioid mu\/delta dual agonist MGM-16, a derivative of the indole alkaloid mitragynine, exhibits potent antiallodynic effect on neuropathic pain in mice","volume":"348","author":"Matsumoto","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fnbeh.2020.582147","article-title":"Drug-induced conditioned place preference and its practical use in substance use disorder research","volume":"14","author":"McKendrick","year":"2020","journal-title":"Front. Behav. Neurosci."},{"key":"10.1016\/j.phrs.2023.106966_bib72","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1080\/14756366.2016.1260565","article-title":"Exploring the first rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors","volume":"32","author":"Mollica","year":"2016","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib73","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1021\/jm5002088","article-title":"Development of a bioavailable mu opioid receptor (MOPr) agonist, delta opioid receptor (DOPr) antagonist peptide that evokes antinociception without development of acute tolerance","volume":"57","author":"Mosberg","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib74","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1021\/jm400050y","article-title":"Opioid peptidomimetics: leads for the design of bioavailable mixed efficacy mu opioid receptor (MOR) agonist\/delta opioid receptor (DOR) antagonist ligands","volume":"56","author":"Mosberg","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib75","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1021\/acs.jmedchem.9b01465","article-title":"Investigation of the adrenergic and opioid binding affinities, metabolic stability, plasma protein binding properties, and functional effects of selected indole-based kratom alkaloids","volume":"63","author":"Obeng","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib76","first-page":"97","article-title":"Novel molecular strategies and targets for opioid drug Discovery for the treatment of chronic pain","volume":"90","author":"Olson","year":"2017","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.phrs.2023.106966_bib77","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1230053","article-title":"Nitro-benzylideneoxymorphone, a bifunctional mu and delta opioid receptor ligand with high mu opioid receptor efficacy","author":"Olson","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib78","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1021\/jm960573f","article-title":"(E)- and (Z)-7-arylidenenaltrexones: synthesis and opioid receptor radioligand displacement assays","volume":"40","author":"Palmer","year":"1997","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib79","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0014-2999(02)02241-0","article-title":"Several \u03b4-opioid receptor ligadns display no subtype selectivity to the human \u03b4-opioid receptor.","volume":"451","author":"Parkhill","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib80","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1016\/j.bmc.2017.07.021","article-title":"Development of novel LP1-based analogues with enhanced delta opioid receptor profile","volume":"25","author":"Pasquinucci","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib81","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.lfs.2013.09.016","article-title":"Novel fentanyl-based dual \u03bc\/\u03b4-opioid agonists for the treatment of acute and chronic pain","volume":"93","author":"Podolski","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.phrs.2023.106966_bib82","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0022-5347(25)00271-X","article-title":"Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2,D-Pen5]enkephalin in the mouse","volume":"241","author":"Porreca","year":"1987","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0014-2999(92)90167-3","article-title":"A highly selective delta 1-opioid receptor antagonist: 7-benzylidenenaltrexone","volume":"218","author":"Portoghese","year":"1992","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib84","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.ejmech.2016.09.077","article-title":"+)- and (\u2013)-Phenazocine enantiomers: evaluation of their dual opioid agoinst\/\u03c31 antagonist properties and antinociceptive effects","volume":"125","author":"Prezzavento","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib85","unstructured":"PRNewswire. Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone. https:\/\/www.prnewswire.com\/news-releases\/tris-pharma-reports-positive-topline-data-from-clinical-study-of-investigational-pain-therapy-cebranopadol-showing-significantly-less-potential-for-abuse-versus-tramadol-and-oxycodone-301701284.html Accessed 14 June 2023."},{"key":"10.1016\/j.phrs.2023.106966_bib86","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00052","article-title":"The delta-opioid receptor: a target for the treatment of pain","volume":"13","author":"Quirion","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2023.106966_bib87","doi-asserted-by":"crossref","unstructured":"Raja, S.N.; Carr, D.B.; Cohen, M.; Finnerup, N.B.; Flor, H.; Gibson, S.; Keefe, F.J.; Mogil, J.S.; Ringkamp, M.; Sluka, K.A.; Song, X.-J.; Stevens, B.; Sullivan, M.D.; Tutelman, P.R.; Ushida, T.; Vader, K. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 161(9): 1976\u20131982.","DOI":"10.1097\/j.pain.0000000000001939"},{"key":"10.1016\/j.phrs.2023.106966_bib88","article-title":"Effects of combined opioids on pain and mood in mammals","volume":"2012","author":"Rech","year":"2012","journal-title":"Pain. Res. Treat."},{"key":"10.1016\/j.phrs.2023.106966_bib89","article-title":"Cebranopadol: a novel, first-in-class, strong analgesic: results from a randomized phase IIa clinical trial in postoperative acute pain","volume":"21","author":"Scholz","year":"2018","journal-title":"Pain. Physician"},{"key":"10.1016\/j.phrs.2023.106966_bib90","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1021\/ml500116x","article-title":"Discovery of spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as potent NOP and opioid receptor agonists","volume":"5","author":"Schunk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106966_bib91","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/ml500117c","article-title":"Discovery of a potent analgesic NOP and opioid receptor agonist: Cebranopadol","volume":"5","author":"Schunk","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106966_bib92","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bph.12774","article-title":"Ligand requirements for involvement of PKC\u03b5 in synergistic analgesic interactions between spinal \u03bc and \u03b4 opioid receptors","volume":"172","author":"Schuster","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopsych.2008.09.009","article-title":"Delta-Opioid Receptor Antagonists Prevent Sensitization to the Conditioned Rewarding Effects of Morphine","volume":"65","author":"Shippenberg","year":"2009","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2023.106966_bib94","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.00054","article-title":"Positive allosteric modulation of CB1 cannabinoid receptor signaling enhances morphine antinociception and attenuates morphine tolerance without enhancing morphine-induced dependence or reward","volume":"13","author":"Slivicki","year":"2020","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.phrs.2023.106966_bib95","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejphar.2014.09.008","article-title":"Targeting putative mu opioid\/metabotropic glutamate receptor-5 heteromers produces potent antinociception in a chronic murine bone cancer model","volume":"743","author":"Smeester","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib96","doi-asserted-by":"crossref","first-page":"5520","DOI":"10.3390\/molecules25235520","article-title":"Multifunctional opioid-derived hybrids in neuropathic pain: preclinical evidence, ideas, and challenges","volume":"25","author":"Starnowska-Sok\u00f3\u0142","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.phrs.2023.106966_bib97","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1124\/jpet.113.203984","article-title":"Effects of spinally administered bifunctional nociceptin\/orphanin FQ peptide receptor\/mu-opioid receptor ligands in mouse models of neuropathic and inflammatory pain","volume":"346","author":"Sukhtankar","year":"2013","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib98","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/aps.2010.164","article-title":"Effects of ATPM-ET, a novel \u03ba agonist with partial \u03bc activity, on morphine-induced physical dependence and behavior sensitization in mice","volume":"31","author":"Sun","year":"2010","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.phrs.2023.106966_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108701","article-title":"Peripheral antinociceptive effects of a bifunctional \u03bc and \u03b4 opioid receptor ligand in a rat model of inflammatory bladder pain","volume":"196","author":"Terashvili","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2023.106966_bib100","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s40263-021-00821-0","article-title":"The NOP receptor system in neurological and psychiatric disorders: discrepancies, peculiarities and clinical progress in developing targeted therapies","volume":"35","author":"Toll","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.phrs.2023.106966_bib101","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/jpet.109.157446","article-title":"Comparison of the antinociceptive and antirewarding profiles of novel bifunctional nociceptin receptor\/mu-opioid receptor ligands: implications for therapeutic applications","volume":"331","author":"Toll","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib102","doi-asserted-by":"crossref","first-page":"8381","DOI":"10.1021\/acs.jmedchem.6b00748","article-title":"Mitragynine\/corynantheidine pseudoindoxyls as opioid analgesics with mu agonism and delta antagonism, which do not recruit beta-arrestin-2","volume":"59","author":"Varadi","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib103","doi-asserted-by":"crossref","first-page":"7663","DOI":"10.1021\/acs.jmedchem.0c00503","article-title":"Synthesis and structure-activity relationships of 5\u2032-aryl-14-alkoxypyridomorphinans: Identification of a \u03bc opioid receptor agonist\/\u03b4 opioid receptor antagonist ligand with systemic antinociceptive activity and diminished opioid side effects","volume":"63","author":"Vekariya","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib104","doi-asserted-by":"crossref","first-page":"7338","DOI":"10.1007\/s12035-019-1607-1","article-title":"Simultaneous activation of mu and delta opioid receptors reduces allodynia and astrocytic Connexin 43 in an animal model of neuropathic pain","volume":"56","author":"Vicario","year":"2019","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2023.106966_bib105","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.apsb.2022.09.018","article-title":"Bispecific sigma-1receptor antagonism and mu-opioid receptor partial agonism: WLB-73502, an analgesic with improved efficacy and safety profile compared to strong opioids","volume":"13","author":"Vidal-Torres","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.phrs.2023.106966_bib106","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges, and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2023.106966_bib107","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1111\/j.1476-5381.2012.02068.x","article-title":"Modulation of gastrointestinal function by MuDelta, a mixed \u03bc opioid receptor agonist\/\u03b4 opioid receptor antagonist","volume":"167","author":"Wade","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib108","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1016\/S0960-894X(98)00472-7","article-title":"Design of a high affinity peptidomimetic opioid agonist from peptide pharmacophore models","volume":"8","author":"Wang","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.phrs.2023.106966_bib109","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1124\/jpet.108.142802","volume":"329","author":"Wang","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib110","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1124\/jpet.115.229971","volume":"357","author":"Wilkerson","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2023.106966_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112144","article-title":"Piperidine propionamide as a scaffold for potent sigma-1 receptor antagonists and mu opioid receptor agonists for treating neuropathic pain","volume":"191","author":"Xiong","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib112","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1213\/ANE.0000000000006266","article-title":"OCP002, a mixed agonist of opioid and cannabinoid receptors, produces potent antinociception with minimized side effects","volume":"136","author":"Xu","year":"2023","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.phrs.2023.106966_bib113","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S0361-9230(01)00550-0","article-title":"SoRI 9409, a non-peptide opioid mu receptor agonist\/delta receptor antagonist, fails to stimulate [35S]-GTP-gamma-S binding at cloned opioid receptors","volume":"55","author":"Xu","year":"2001","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.phrs.2023.106966_bib114","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejphar.2019.04.009","article-title":"Delta-opioid receptor antagonist naltrindole reduces oxycodone addiction and constipation in mice","volume":"852","author":"Yang","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2023.106966_bib115","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1097\/AJP.0000000000000417","article-title":"Sebacoyl dinalbuphine ester extended-release injection for long-acting analgesia: a multicenter, randomized, double-blind, and placebo-controlled study in hemorrhoidectomy patients","volume":"33","author":"Yeh","year":"2017","journal-title":"Clin. J. Pain."},{"key":"10.1016\/j.phrs.2023.106966_bib116","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0896-6273(00)80836-3","article-title":"Retention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout mice","volume":"24","author":"Zhu","year":"1999","journal-title":"Neuron"},{"key":"10.1016\/j.phrs.2023.106966_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113658","article-title":"Bifunctional \u03bc opioid and \u03c31 receptor ligands as novel analgesics with reduced side effects","volume":"223","author":"Zhuang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.phrs.2023.106966_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114649","article-title":"Benzylaminofentanyl derivatives: discovery of bifunctional \u03bc opioid and \u03c31 receptor ligands as novel analgesics with reduced adverse effects.","volume":"241","author":"Zhuang","year":"2022","journal-title":"Eur. J. Med. Chem."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003225?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661823003225?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:49:52Z","timestamp":1760914192000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661823003225"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":118,"alternative-id":["S1043661823003225"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106966","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IUPHAR Review - Bivalent and bifunctional opioid receptor ligands as novel analgesics","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2023.106966","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106966"}}